Correction: Combating subclonal evolution of resistant cancer phenotypes (Nature Communications (2017) DOI: 10.1038/s41467-017-01174-3);Combating subclonal evolution of resistant cancer phenotypes

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  Brady, Samuel W ^a,b   McQuerry, Jasmine A ^a,b   Qiao, Yi ^b   Piccolo, Stephen R ^a,b,c   Shrestha, Gajendra ^a   Jenkins, David F ^d   Layer, Ryan M ^b   Pedersen, Brent S ^b   Miller, Ryan H ^b   Esch, Amanda ^e,f   Selitsky, Sara R ^g   Parker, Joel S ^g   Anderson, Layla A ^a   Dalley, Brian K ^h   Factor, Rachel E ^b   Reddy, Chakravarthy B ^b   Boltax, Jonathan P ^b   Li, Dean Y ^b   Moos, Philip J ^a   Gray, Joe W ^e,f   Heiser, Laura M ^e,f   Buys, Saundra S ^b   Cohen, Adam L ^b   Johnson, W Evan ^b,d   Quinlan, Aaron R ^b   Marth, Gabor ^b   Werner, Theresa L ^b   Bild, Andrea H ^a,b,i   more..

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c BRIGHAM YOUNG UNIVERSITY   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Oregon Health and Science University Department of Biomedical Engineering   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF UTAH   (United States)

ⁱ City of Hope Comprehensive Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE; BRCA2 PROTEIN; CAPECITABINE; CARBOPLATIN; CELL DNA; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERIBULIN; EVEROLIMUS; EXEMESTANE; FULVESTRANT; GEMCITABINE; INTERFERON; LETROZOLE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; OLAPARIB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; RNA; SMAD4 PROTEIN; TAMOXIFEN; TRASTUZUMAB; TUMOR NECROSIS FACTOR; VINORELBINE TARTRATE;

ANTIGEN; CANCER; CHEMOTHERAPY; DRUG RESISTANCE; IMMUNE SYSTEM; PHENOTYPE; TUMOR;

5' UNTRANSLATED REGION; ANTIGEN PRESENTATION; ARTICLE; ASCITES; CANCER PATIENT; CANCER RESISTANCE; CASE REPORT; CHROMOSOME 10; CHROMOSOME 2; CHROMOSOME DELETION; CLINICAL ARTICLE; DNA CONTENT; DNA SEQUENCE; DRUG RESPONSE; GENE; GENE FREQUENCY; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOSITY LOSS; HUMAN; INTRADUCTAL CARCINOMA; MALIGNANT PLEURA EFFUSION; METASTATIC BREAST CANCER; MUTAGENESIS; PLEURA EFFUSION; PROMOTER REGION; RNA SEQUENCE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TGFBR2 GENE; WHOLE EXOME SEQUENCING; WHOLE GENOME SEQUENCING; BREAST TUMOR; CELL CULTURE; CLONAL EVOLUTION; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SEQUENCING; MUTATION; PATHOLOGY; PHENOTYPE; PROCEDURES; SINGLE CELL ANALYSIS;

BREAST NEOPLASMS; CELLS, CULTURED; CLONAL EVOLUTION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; PHENOTYPE; SIGNAL TRANSDUCTION; SINGLE-CELL ANALYSIS;

EID: 85032882687     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-02383-6     Document Type: Erratum

References (68)

1. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
2. Fisher, R., Pusztai, L. & Swanton, C. Cancer heterogeneity: implications for targeted therapeutics. Br. J. Cancer 108, 479-485 (2013).
3. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558 (2013).
4. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
5. Sequist, L. V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011).
6. Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69-80 (2010).
7. Patch, A.-M. et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521, 489-494 (2015).
8. Yates, L. R. et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat. Med. 21, 751-759 (2015).
9. Cardoso, F. et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23, vii11-vii19 (2012).
10. Zardavas, D., Irrthum, A., Swanton, C. & Piccart, M. Clinical management of breast cancer heterogeneity. Nat. Rev. Clin. Oncol. 12, 381-394 (2015).
11. Qiao, Y. et al. SubcloneSeeker: a computational framework for reconstructing tumor clone structure for cancer variant interpretation and prioritization. Genome Biol. 15, 443 (2014).
12. Forbes, S. A. et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 43, D805-D811 (2015).
13. McDonagh, C. F. et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol. Cancer Ther. 11, 582-593 (2012).
14. Robinson, D. R. et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 45, 1446-1451 (2013).
15. Gottesman, M. M., Fojo, T. & Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2, 48-58 (2002).
16. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
17. Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S. & Swanton, C. deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31 (2016).
18. Sakai, W. et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451, 1116-1120 (2008).
19. Ellis, M. J. et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486, 353-360 (2012).
20. Norquist, B. et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol. 29, 3008-3015 (2011).
21. Barber, L. J. et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J. Pathol. 229, 422-429 (2013).
22. de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251-256 (2014).
23. Navin, N. et al. Tumour evolution inferred by single-cell sequencing. Nature 472, 90-94 (2011).
24. Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189-196 (2016).
25. Peterson, V. M. et al. Ascites analysis by a microfluidic chip allows tumor-cell profiling. Proc. Natl Acad. Sci. USA 110, E4978-E4986 (2013).
26. LaRocca, P. J. & Rheinwald, J. G. Coexpression of simple epithelial keratins and vimentin by human mesothelium and mesothelioma in vivo and in culture. Cancer Res. 44, 2991-2999 (1984).
27. Svensson, V. et al. Power analysis of single-cell RNA-sequencing experiments. Nat. Methods 14, 381-387 (2017).
28. Fan, J. et al. Characterizing transcriptional heterogeneity through pathway and gene set overdispersion analysis. Nat. Methods 13, 241-244 (2016).
29. Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739-1740 (2011).
30. Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108-112 (2009).
31. Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715 (2008).
32. Scheurich, P., Thoma, B., Ucer, U. & Pfizenmaier, K. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses. J. Immunol. 138, 1786-1790 (1987).
33. Romero, J. M. et al. Coordinated downregulation of the antigen presentation machinery and HLA class I/β2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. Int. J. Cancer 113, 605-610 (2005).
34. Lemmon, M. A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 141, 1117-1134 (2010).
35. Rahman, M. et al. Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes. Genome Med. 9, 40 (2017).
36. Shan, L., Yu, M., Qiu, C. & Snyderwine, E. G. Id4 regulates mammary epithelial cell growth and differentiation and is overexpressed in rat mammary gland carcinomas. Am. J. Pathol. 163, 2495-2502 (2003).
37. Vereecke, L., Beyaert, R. & van Loo, G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 30, 383-391 (2009).
38. Kaer, L. Van, Ashton-Rickardt, P. G., Ploegh, H. L. & Tonegawa, S. TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-8+T cells. Cell 71, 1205-1214 (1992).
39. Serreze, D. V., Leiter, E. H., Christianson, G. J., Greiner, D. & Roopenian, D. C. Major histocompatibility complex class I-deficient NOD-B2mnull mice are diabetes and insulitis resistant. Diabetes 43, 505-509 (1994).
40. Lee, J.-K. et al. Spatiotemporal genomic architecture informs precision oncology in glioblastoma. Nat. Genet. 49, 594-599 (2017).
41. Sukumar, S. et al. Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature 405, 974-978 (2000).
42. Asati, V., Mahapatra, D. K. & Bharti, S. K. PI3K/Akt/mTOR and Ras/Raf/MEK/ ERK signaling pathways inhibitors as anticancer agents: structural and pharmacological perspectives. Eur. J. Med. Chem. 109, 314-341 (2016).
43. Liu, X. et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am. J. Pathol. 180, 599-607 (2012).
44. Crystal, A. S. et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346, 1480-1486 (2014).
45. Chappell, W. H. et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2, 135-164 (2011).
46. Hafner, M., Niepel, M., Chung, M. & Sorger, P. K. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat. Methods 13, 521-527 (2016).
47. Katayama, R. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci. Transl. Med. 4, 120ra17 (2012).
48. Camidge, D. R., Pao, W. & Sequist, L. V. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat. Rev. Clin. Oncol. 11, 473-481 (2014).
49. Shaw, A. T. et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N. Engl. J. Med. 374, 54-61 (2016).
50. Chandarlapaty, S. et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19, 58-71 (2011).
51. Duncan, J. S. et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 149, 307-321 (2012).
52. Amin, D. N. et al. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci. Transl. Med. 2, 16ra7 (2010).
53. Chmielecki, J. et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci. Transl. Med. 3, 90ra59 (2011).
54. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114-2120 (2014).
55. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
56. Barnett, D. W., Garrison, E. K., Quinlan, A. R., Strömberg, M. P. & Marth, G. T. BamTools: a C++API and toolkit for analyzing and managing BAM files. Bioinformatics 27, 1691-1692 (2011).
57. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010).
58. Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568-576 (2012).
59. Garrison, E. & Marth, G. Haplotype-based variant detection from short-read sequencing. Preprint at https://arxiv.org/abs/1207.3907 (2012).
60. Layer, R. M., Chiang, C., Quinlan, A. R. & Hall, I. M. LUMPY: a probabilistic framework for structural variant discovery. Genome Biol. 15, R84 (2014).
61. Wilkerson, M. D. et al. Integrated RNA and DNA sequencing improves mutation detection in low purity tumors. Nucleic Acids Res. 42, e107-e107 (2014).
62. Hoadley, K. A. et al. Tumor evolution in two patients with basal-like breast cancer: a retrospective genomics study of multiple metastases. PLoS Med. 13, e1002174 (2016).
63. Bodenhofer, U., Kothmeier, A. & Hochreiter, S. APCluster: an R package for affinity propagation clustering. Bioinformatics 27, 2463-2464 (2011).
64. Liao, Y., Smyth, G. K. & Shi, W. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res. 41, e108 (2013).
65. Shen, Y. et al. ASSIGN: context-specific genomic profiling of multiple heterogeneous biological pathways. Bioinformatics 31, 1745-1753 (2015).
66. Czabotar, P. E., Lessene, G., Strasser, A. & Adams, J. M. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat. Rev. Mol. Cell Biol. 15, 49-63 (2014).
67. Srinivasula, S. M. & Ashwell, J. D. IAPs: what's in a name? Mol. Cell 30, 123-135 (2008).
68. Kim, D. & Salzberg, S. L. TopHat-Fusion: an algorithm for discovery of novel fusion transcripts. Genome Biol. 12, R72 (2011).